FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229960078> ?p ?o ?g. }

• W4229960078 endingPage "154" @default.
• W4229960078 startingPage "154" @default.
• W4229960078 abstract "Abstract Background This study aimed to determine the benefit of early therapeutic intervention with the combination of elotuzumab, Lenalidomide, and Dexamethasone in patients with high-risk smoldering multiple myeloma (SMM). ClinicalTrials.gov Identifier: NCT02279394. Aims The overarching objective of this trial is to determine progression free survival to symptomatic multiple myeloma (MM). Furthermore, the study examined whether genomic studies can help in determining patients who would benefit the most from this early therapeutic intervention. Methods Patients enrolled in this study met eligibility for high-risk SMM based on the newly defined criteria proposed by Rajkumar et al, Blood 2014. Patients were administered weekly elotuzumab (10 mg/kg) on days 1, 8, 15, and 22 for the first two 28-day cycles while receiving lenalidomide on days 1-21. For cycles 3-8, patients were administered elotuzumab infusions on days 1, 8, and 15. dexamethasone (40mg) was given on days 1, 8 and 15 to 40 of the 50 enrolled patients. After 8 cycles or best response, patients were given the option to mobilize with either cyclophosphamide or plerixafor and collect stem cells for future transplant. Patients were then allowed to continue on maintenance therapy where they were administered elotuzumab (20 mg/kg) on day 1, in combination with lenalidomide days 1-21 of a 28-day cycle. Bone marrow (BM) samples of 32 patients were obtained before starting therapy for baseline assessment and whole exome sequencing (WES) of plasma cells. Results In total, 50 patients were enrolled on this study from January 2015 and completed accrual in December 2016, with the participation of eight sites. The median age of enrolled patients was 62 years (range, 29-79) with 18 males (36%) and 32 females (64%). Interphase fluorescence in situ hybridization (iFISH) detected high-risk cytogenetics (defined by the presence of 17p deletion, t(4;14), and 1q gain) in 20 patients. The median time to response was 2.8 months (range, 1.8-4.6). The most common toxicities were fatigue (92%), followed by diarrhea (72%), and hyperglycemia (62%). The most common grade 3 or more adverse events were hypophosphatemia (34%), neutropenia (26%), and lymphocyte count decreased (22%). Three patients (6%) had grade 4 hypophosphatemia during treatment. Additionally, grade 4 cholecystitis, cataract, lymphocyte count increase, hyperglycemia, neutropenia, and thrombocytopenia occurred in one patient (2%). Diabetic Ketoacidosis and sepsis led to death in a patient (2%). Stem cell collection was successful in all mobilized patients to date. As of this abstract date, the overall response rate is 84% (41/49). There were 3 complete responses (6%), 18 very good partial responses (37%), 20 partial responses (41%), 5 minimal responses (10%), 3 stable disease (6%), and 2 unevaluable patients. All the study participants except for three have finished treatment and are currently under follow up. None of the patients showed progression to overt MM to date. We continue to collect data for progression free survival. WES was performed on 32 samples at the time of initiation of therapy. Recurrent mutations in the MAPK pathway (KRAS, NRAS) and tumor suppressor gene, TP53, were detected in 40% of the cases (16% and 24%, respectively), while mutations in the NF-KB and plasma cell differentiation pathways were present in 13% of patients. Somatic copy number alterations (SCNAs) were called based on WES: 1q duplication, 13q, 17p, and 1p deletions were identified in 25, 31, 12, and 7% of cases, respectively. Interestingly, in 6 patients, high-risk SCNAs (1q gain and 17p deletion) were not reported in iFISH but were detected by WES. The analysis of these 32 samples showed that patients who are harboring mutations in the DNA repair pathway genes, had modest response to treatment. Finally, we are analyzing the transcriptomic profile of CD138 negative cells, which represent the BM microenvironment cells (immune and stromal cells) to characterize the BM microenvironment at baseline and end of treatment, and thus, elucidate the role of these cells in the differential response to therapy. Conclusion The combination of elotuzumab, lenalidomide, and dexamethasone is well tolerated and demonstrates a high response rate with no progression to overt MM to date. Correlation with genomic studies can help define patients who benefit the most from this early therapeutic intervention. Disclosures Ghobrial: Takeda: Consultancy; Janssen: Consultancy; BMS: Consultancy; Celgene: Consultancy. Bustoros:Dava Oncology: Honoraria. Badros:GSK: Research Funding; Celgene: Consultancy, Research Funding; Karyopharm: Research Funding. Matous:Celgene: Consultancy, Honoraria, Speakers Bureau. Rosenblatt:Merck: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Research Funding; Celgene: Research Funding; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees. Jakubowiak:Karyopharm: Consultancy, Honoraria; SkylineDx: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Adaptive Biotechnologies: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Usmani:Abbvie, Amgen, Celgene, Genmab, Merck, MundiPharma, Janssen, Seattle Genetics: Consultancy; Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics,Sanofi, Seattle Genetics, Takeda: Research Funding. Zonder:Celgene: Consultancy, Honoraria; Pharmacyclics: Other: DSMC; Janssen: Honoraria; Takeda: Honoraria; Alnylam: Honoraria; Coelum: Honoraria; BMS: Research Funding. Munshi:OncoPep: Other: Board of director. Anderson:Gilead: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy; C4 Therapeutics: Equity Ownership, Other: Scientific founder; OncoPep: Equity Ownership, Other: Scientific founder; Millennium Takeda: Consultancy; Celgene: Consultancy. Richardson:Amgen: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W4229960078 created "2022-05-11" @default.
• W4229960078 creator A5000301432 @default.
• W4229960078 creator A5000620040 @default.
• W4229960078 creator A5003087873 @default.
• W4229960078 creator A5007203239 @default.
• W4229960078 creator A5008397526 @default.
• W4229960078 creator A5009378735 @default.
• W4229960078 creator A5009765944 @default.
• W4229960078 creator A5012186826 @default.
• W4229960078 creator A5014505996 @default.
• W4229960078 creator A5014871120 @default.
• W4229960078 creator A5017383524 @default.
• W4229960078 creator A5018004262 @default.
• W4229960078 creator A5019827043 @default.
• W4229960078 creator A5023152679 @default.
• W4229960078 creator A5023955059 @default.
• W4229960078 creator A5025940697 @default.
• W4229960078 creator A5027328800 @default.
• W4229960078 creator A5034791164 @default.
• W4229960078 creator A5036597239 @default.
• W4229960078 creator A5036677725 @default.
• W4229960078 creator A5038614792 @default.
• W4229960078 creator A5045179755 @default.
• W4229960078 creator A5046713411 @default.
• W4229960078 creator A5049433553 @default.
• W4229960078 creator A5049711954 @default.
• W4229960078 creator A5049900530 @default.
• W4229960078 creator A5052163068 @default.
• W4229960078 creator A5052819968 @default.
• W4229960078 creator A5054083729 @default.
• W4229960078 creator A5054346063 @default.
• W4229960078 creator A5054484092 @default.
• W4229960078 creator A5055000089 @default.
• W4229960078 creator A5055089118 @default.
• W4229960078 creator A5057911528 @default.
• W4229960078 creator A5064710410 @default.
• W4229960078 creator A5069306856 @default.
• W4229960078 creator A5070964766 @default.
• W4229960078 creator A5072115247 @default.
• W4229960078 creator A5075607061 @default.
• W4229960078 creator A5087492053 @default.
• W4229960078 creator A5088396920 @default.
• W4229960078 creator A5028131599 @default.
• W4229960078 date "2018-11-29" @default.
• W4229960078 modified "2023-10-01" @default.
• W4229960078 title "Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma" @default.
• W4229960078 doi "https://doi.org/10.1182/blood-2018-154" @default.
• W4229960078 hasPublicationYear "2018" @default.
• W4229960078 type Work @default.
• W4229960078 citedByCount "16" @default.
• W4229960078 countsByYear W42299600782019 @default.
• W4229960078 countsByYear W42299600782020 @default.
• W4229960078 countsByYear W42299600782021 @default.
• W4229960078 countsByYear W42299600782022 @default.
• W4229960078 countsByYear W42299600782023 @default.
• W4229960078 crossrefType "journal-article" @default.
• W4229960078 hasAuthorship W4229960078A5000301432 @default.
• W4229960078 hasAuthorship W4229960078A5000620040 @default.
• W4229960078 hasAuthorship W4229960078A5003087873 @default.
• W4229960078 hasAuthorship W4229960078A5007203239 @default.
• W4229960078 hasAuthorship W4229960078A5008397526 @default.
• W4229960078 hasAuthorship W4229960078A5009378735 @default.
• W4229960078 hasAuthorship W4229960078A5009765944 @default.
• W4229960078 hasAuthorship W4229960078A5012186826 @default.
• W4229960078 hasAuthorship W4229960078A5014505996 @default.
• W4229960078 hasAuthorship W4229960078A5014871120 @default.
• W4229960078 hasAuthorship W4229960078A5017383524 @default.
• W4229960078 hasAuthorship W4229960078A5018004262 @default.
• W4229960078 hasAuthorship W4229960078A5019827043 @default.
• W4229960078 hasAuthorship W4229960078A5023152679 @default.
• W4229960078 hasAuthorship W4229960078A5023955059 @default.
• W4229960078 hasAuthorship W4229960078A5025940697 @default.
• W4229960078 hasAuthorship W4229960078A5027328800 @default.
• W4229960078 hasAuthorship W4229960078A5028131599 @default.
• W4229960078 hasAuthorship W4229960078A5034791164 @default.
• W4229960078 hasAuthorship W4229960078A5036597239 @default.
• W4229960078 hasAuthorship W4229960078A5036677725 @default.
• W4229960078 hasAuthorship W4229960078A5038614792 @default.
• W4229960078 hasAuthorship W4229960078A5045179755 @default.
• W4229960078 hasAuthorship W4229960078A5046713411 @default.
• W4229960078 hasAuthorship W4229960078A5049433553 @default.
• W4229960078 hasAuthorship W4229960078A5049711954 @default.
• W4229960078 hasAuthorship W4229960078A5049900530 @default.
• W4229960078 hasAuthorship W4229960078A5052163068 @default.
• W4229960078 hasAuthorship W4229960078A5052819968 @default.
• W4229960078 hasAuthorship W4229960078A5054083729 @default.
• W4229960078 hasAuthorship W4229960078A5054346063 @default.
• W4229960078 hasAuthorship W4229960078A5054484092 @default.
• W4229960078 hasAuthorship W4229960078A5055000089 @default.
• W4229960078 hasAuthorship W4229960078A5055089118 @default.
• W4229960078 hasAuthorship W4229960078A5057911528 @default.
• W4229960078 hasAuthorship W4229960078A5064710410 @default.
• W4229960078 hasAuthorship W4229960078A5069306856 @default.
• W4229960078 hasAuthorship W4229960078A5070964766 @default.
• W4229960078 hasAuthorship W4229960078A5072115247 @default.
• W4229960078 hasAuthorship W4229960078A5075607061 @default.
• W4229960078 hasAuthorship W4229960078A5087492053 @default.

• next